A new ground-breaking technology was recently used at the University of Ottawa Heart Institute (UOHI) where two cardiologists, Dr. David Birnie and Dr. Pablo Nery, implanted a new innovative leadless defibrillator, the subcutaneous implantable cardioverter defibrillator (S-ICD), to a 18 year-old patient. Under Health Canada‘s special access program, this was only the third time this new type of ICD had been implanted in Canada.
Conventional defibrillators, known as transvenous defibrillators, are implanted with wires, called the leads, that snake through veins into the heart. When the defibrillator identifies any dangerous heartbeat, it delivers a shock through the wires to return the heart to its normal rhythm and allow it to get back to pumping blood steadily throughout the body.
Not all patients are suitable for a conventional defibrillator. In some with congenital heart problems, there is no way to advance the leads into the heart through the veins. Also, those wires may pose a danger due to the risk of blood clots or infection. Patients often have to undergo a more complex and invasive surgery to attach the leads to the outer layer of the heart muscle in order to benefit from the use of a defibrillator
This image shows Dr. Pablo Nery and Dr. David Birnie from the University of Ottawa Heart Institute.
Conventional ICDs use leads that run from the device through major veins to an anchor point in the heart. These transvenous leads can cause problems in the long term. Despite decades of design improvements, leads can malfunction, break or stop working. Known as lead failure, this results in either inappropriate shocks or lack of proper regulation of the heartbeat. What’s worse is that failed leads often must be removed, which poses serious risks to the patient.
What makes the new device special is that it is entirely subcutaneous. No part of it actually touches the heart. Instead, an electrode is implanted just under the skin near the heart. The defibrillator is connected to the electrode, and monitors the heartbeat at all times. If needed, it delivers a shock to the heart muscle to restore its normal rhythm.
This chest X-ray shows the third subcutaneous implantable cardiac defibrillator (S-ICD) in Canada located under the skin of an 18-year-old patient with congenital heart disease. The electrode can be seen positioned near the heart, but unlike standard ICDs, no part of the device actually touches the heart.
The goal of the subcutaneous ICD is to potentially reduce or eliminate these problems. “The subcutaneous ICD provides effective therapy for patients who are either not eligible for or are at high risk with a traditional ICD. Such patients may now be able to receive protection from a subcutaneous ICD without the risks associated with the standard leads,” explained Dr. Nery.
That made the 18-year-old recipient of the S-ICD at the Heart Institute a perfect candidate. “The S-ICD offers advantages for particular patient sub-groups,” said Dr. Nery. “This technology is now an alternative for young patients, in part because lead extraction can be avoided down the road.”
Another advantage is more aesthetic in nature but, nonetheless, important for young people. A conventional transvenous defibrillator sits on the front on the chest, just under the collarbone, and is easy to see. The S-ICD, in comparison, is implanted to the side, under the patient’s arm, and with a much smaller incision than with the transvenous defibrillator. That, said Dr. Nery, is an important consideration for many patients in terms of body image and quality of life.
Related articles
